A Phase II Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Breast - Female | Breast - Male | Lung | Pancreas | Phase I
What is the purpose of this trial?
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by surgery, including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.
- Trial withNational Cancer Institute
- Start Date08/11/2016
- End Date06/29/2019
- Last Updated10/09/2018
- Study HIC#1604017576